DK0656883T3 - Kationiske lipider - Google Patents

Kationiske lipider

Info

Publication number
DK0656883T3
DK0656883T3 DK93920406T DK93920406T DK0656883T3 DK 0656883 T3 DK0656883 T3 DK 0656883T3 DK 93920406 T DK93920406 T DK 93920406T DK 93920406 T DK93920406 T DK 93920406T DK 0656883 T3 DK0656883 T3 DK 0656883T3
Authority
DK
Denmark
Prior art keywords
useful
cationic lipids
lipids
macromolecules
delivery
Prior art date
Application number
DK93920406T
Other languages
English (en)
Inventor
Gulilat Gebeyehu
Joel A Jessee
Valentina C Ciccarone
Pamela Hawley-Nelson
Anna Chytil
Original Assignee
Life Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Inc filed Critical Life Technologies Inc
Application granted granted Critical
Publication of DK0656883T3 publication Critical patent/DK0656883T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK93920406T 1992-08-28 1993-08-27 Kationiske lipider DK0656883T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/937,508 US5334761A (en) 1992-08-28 1992-08-28 Cationic lipids
PCT/US1993/008130 WO1994005624A1 (en) 1992-08-28 1993-08-27 Cationic lipids

Publications (1)

Publication Number Publication Date
DK0656883T3 true DK0656883T3 (da) 1999-10-18

Family

ID=25470017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93920406T DK0656883T3 (da) 1992-08-28 1993-08-27 Kationiske lipider

Country Status (10)

Country Link
US (1) US5334761A (da)
EP (1) EP0656883B1 (da)
JP (1) JP3210019B2 (da)
AT (1) ATE178584T1 (da)
CA (1) CA2141334C (da)
DE (1) DE69324367T2 (da)
DK (1) DK0656883T3 (da)
ES (1) ES2132253T3 (da)
GR (1) GR3030206T3 (da)
WO (1) WO1994005624A1 (da)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
US7323297B1 (en) * 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
EP1624068A1 (en) * 1993-06-01 2006-02-08 Life Technologies Inc. Genetic immunization with cationic lipids
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5399746A (en) * 1994-02-07 1995-03-21 Witco Corporation Diquaternary bleach activators and compositions containing them
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
CA2194221C (en) * 1994-06-22 2001-01-02 Timothy D. Heath Cationic amphiphiles
US5777153A (en) * 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5892071A (en) * 1994-09-30 1999-04-06 The Reagents Of The University Of California Cationic transport reagents
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6107457A (en) 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
EP0824362A1 (en) * 1995-02-28 1998-02-25 Nature Technology Corporation Biosynthetic virus vectors for gene therapy
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US5759519A (en) * 1995-06-07 1998-06-02 Gen-Probe Incorporated Method for the intracellular delivery of biomolecules using thiocationic lipids
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
US5711964A (en) * 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
AU705549B2 (en) 1995-06-07 1999-05-27 Promega Biosciences, Inc. Phosphonic acid-based cationic lipids
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0830368A1 (en) * 1995-06-07 1998-03-25 Genta Incorporated Novel carbamate-based cationic lipids
US5851548A (en) * 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
CA2223921A1 (en) * 1995-06-07 1996-12-19 Francis C. Szoka, Jr. Stabilization of polynucleotide complexes
US5756352A (en) * 1995-06-07 1998-05-26 Gen-Probe Incorporated Thiocationic lipid-nucleic acid conjugates
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
NZ313839A (en) * 1995-07-21 1998-12-23 Genta Inc Amide-based cationic lipids
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5869715A (en) * 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
AU7078396A (en) * 1995-09-27 1997-04-30 Regents Of The University Of California, The Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
JP4430135B2 (ja) * 1995-11-30 2010-03-10 バイカル インコーポレイテッド カチオン脂質複合体
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
US5994317A (en) * 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
JP3919227B2 (ja) 1996-05-02 2007-05-23 テルモ株式会社 アミジン誘導体及びそれを構成成分とする薬物担体
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
DE69725878T2 (de) * 1996-08-13 2004-07-29 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzungen zur polynukleotidabgabe
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
US7097854B2 (en) 1996-09-12 2006-08-29 Medigene Oncology Gmbh Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds
EP1254657B1 (en) * 1996-09-13 2008-05-21 Lipoxen Technologies Limited Liposomes
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
FR2759367A1 (fr) * 1997-02-10 1998-08-14 Transgene Sa Glycerolipides cationiques et complexes de glycerolipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
WO1998038326A1 (en) 1997-02-28 1998-09-03 Nature Technology Corporation Self-assembling genes, vectors and uses thereof
FR2760193B1 (fr) * 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
WO1998056353A1 (en) * 1997-06-13 1998-12-17 Navid Malik Internally supported lipid vesicle systems
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US20030073640A1 (en) * 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6197332B1 (en) * 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
WO1999008997A1 (de) * 1997-08-13 1999-02-25 Biontex Laboratories Gmbh Neue lipopolyamine, deren darstellung und anwendung
AU9404398A (en) * 1997-09-23 1999-04-12 Megabios Corporation Methods for preparing lipids/polynucleotide transfection complexes
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
ATE550042T1 (de) 1997-11-20 2012-04-15 Vical Inc Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6043390A (en) 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
AU768542C (en) * 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
WO2000012454A1 (en) * 1998-08-27 2000-03-09 Alberto Haces Novel polycationic lipids
JP2002524473A (ja) 1998-09-09 2002-08-06 ジエンザイム コーポレイション プラスミドベクターのメチル化
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
EP2298728A1 (en) 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
ATE397942T1 (de) * 1999-03-26 2008-07-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
AU778737B2 (en) * 1999-04-14 2004-12-16 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US7504253B2 (en) * 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
US20010048940A1 (en) * 1999-06-18 2001-12-06 Jennifer D. Tousignant Cationic amphiphile micellar complexes
US6830902B1 (en) * 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CA2395839A1 (en) * 1999-12-27 2001-07-05 The Regents Of The University Of California Gene therapy for congestive heart failure
JP2003519199A (ja) * 1999-12-30 2003-06-17 ノバルティス アクチエンゲゼルシャフト 遺伝子治療のための新規なコロイド合成ベクター
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002019822A1 (en) * 2000-09-08 2002-03-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
CA2427068A1 (en) * 2000-10-27 2002-05-02 Invitrogen Corporation Method for introducing antisense oligonucleotides into eucaryotic cells
US20030170642A1 (en) * 2001-03-12 2003-09-11 Irm, Llc Identification of cellular targets for biologically active molecules
US20040076954A1 (en) * 2001-03-12 2004-04-22 Irm, Llc Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US6936469B2 (en) 2001-03-22 2005-08-30 Chromos Molecular Systems Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030186390A1 (en) * 2001-03-22 2003-10-02 De Jong Gary Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
CA2445947A1 (en) * 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
AU2002327430A1 (en) * 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
JP2005525375A (ja) * 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法
US7598421B2 (en) * 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
WO2004002416A2 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
ES2439727T3 (es) * 2002-10-29 2014-01-24 Insmed Incorporated Liberación sostenida de antiinfectantes
CN101104594A (zh) * 2002-12-26 2008-01-16 盐野义制药株式会社 用捕捉糖链的分子纯化/浓缩糖链的方法和分析糖链结构的方法
WO2004063342A2 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
JP2004337400A (ja) * 2003-05-16 2004-12-02 Terumo Corp 薬剤投与キット
US7531693B2 (en) * 2003-05-22 2009-05-12 Molecular Transfer, Inc. Lipids for transfection of nucleic acids
BRPI0410915A (pt) * 2003-06-04 2006-06-27 Canji Inc composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit
US8242089B2 (en) * 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection
US7906122B2 (en) * 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
FR2858628B1 (fr) * 2003-08-04 2008-01-04 Polyplus Transfection Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
US7330851B2 (en) * 2003-08-18 2008-02-12 Eaglehawk, Limited Data security through dissembly of data elements or connections between elements
NZ592917A (en) * 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
JP4796062B2 (ja) * 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉ｒｎａ
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2007008220A2 (en) * 2004-08-05 2007-01-18 Baylor Research Institute Gene or drug delivery system
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9149543B2 (en) * 2005-12-15 2015-10-06 The Trustees Of The University Of Pennsylvania Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
CA2651389C (en) 2006-05-05 2017-04-25 Molecular Transfer, Inc. Novel reagents for transfection of eukaryotic cells
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CN101674853B (zh) 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2008144664A1 (en) * 2007-05-18 2008-11-27 Brooks Automation, Inc. Compact substrate transport system with fast swap robot
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
JP2011502162A (ja) * 2007-10-29 2011-01-20 ザ ユニバーシティー オブ カリフォルニア 変形性関節症遺伝子治療
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
WO2009065618A2 (de) 2007-11-22 2009-05-28 Biontex Laboratories Gmbh Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
ES2535419T3 (es) * 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
CA3044134A1 (en) * 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
DK2279254T3 (da) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc Hidtil ukendte lipidformuleringer til nukleinsyreindgivelse
JP5971945B2 (ja) 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質の鏡像異性体による免疫応答の刺激
WO2009155100A1 (en) 2008-05-30 2009-12-23 Yale University Targeted oligonucleotide compositions for modifying gene expression
CA2984026C (en) 2008-10-09 2020-02-11 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
JP2012505913A (ja) 2008-10-16 2012-03-08 マリーナ バイオテック，インコーポレイテッド 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US9023820B2 (en) 2009-01-26 2015-05-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein C-III expression
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
TR201901311T4 (tr) 2009-12-01 2019-02-21 Translate Bio Inc İnsan genetik hastalıklarında mRNA'nın teslimi için steroid türevi.
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
JP5510808B2 (ja) * 2010-03-10 2014-06-04 独立行政法人産業技術総合研究所 有機ナノチューブからなる核酸導入剤
US9247720B2 (en) 2010-03-24 2016-02-02 Institut National de la Santé et de la Recherche Médicale Primate model from the family cercopithecidae infected by a HBV strain of human genotype
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
CN103380113B (zh) 2010-11-15 2018-03-30 生命科技公司 含胺的转染试剂及其制备和使用方法
NZ703649A (en) 2010-12-06 2016-08-26 Penn State Res Found Compositions and methods relating to proliferative diseases
PL2691443T3 (pl) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Sprzężone lipomery i ich zastosowania
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
WO2013040517A2 (en) 2011-09-15 2013-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH
CA3119789A1 (en) 2011-10-27 2013-05-02 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
DK2830595T3 (da) 2012-03-29 2019-12-02 Translate Bio Inc Ioniserbare kationiske lipider
AU2013237874B2 (en) 2012-03-29 2018-01-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
CN108743537B (zh) 2012-05-21 2021-06-11 英斯麦德公司 治疗肺部感染的系统
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2858679B1 (en) 2012-06-08 2021-02-24 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
JP6108197B2 (ja) * 2012-07-02 2017-04-05 日油株式会社 三級アミノ基含有脂質の製造方法
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
JP2015530413A (ja) 2012-09-21 2015-10-15 ベデュ−アッド，フランク 改良されたワクチン組成物および使用方法
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
ES2692363T3 (es) 2013-03-14 2018-12-03 Translate Bio, Inc. Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
BR112015022660A2 (pt) 2013-03-14 2017-10-31 Shire Human Genetic Therapies métodos para a purificação de rna mensageiro
BR112015022868B1 (pt) 2013-03-14 2023-05-16 Ethris Gmbh Composições de mrna de cftr e usos e métodos relacionados
SI2970456T1 (sl) 2013-03-14 2022-01-31 Translate Bio, Inc. Postopki in sestavki za dostavo MRNA-kodiranih protiteles
ES2670529T3 (es) 2013-03-15 2018-05-30 Translate Bio, Inc. Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
WO2014142995A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
WO2014143031A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
JP2016529284A (ja) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
SG11201602943PA (en) 2013-10-22 2016-05-30 Shire Human Genetic Therapies Lipid formulations for delivery of messenger rna
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
US20150110857A1 (en) 2013-10-22 2015-04-23 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
CA2928188A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
SG10201811729PA (en) 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
EP3450553B1 (en) 2014-03-24 2019-12-25 Translate Bio, Inc. Mrna therapy for treatment of ocular diseases
BR112016024632A2 (pt) 2014-04-25 2018-01-30 Shire Human Genetic Therapies métodos de purificação de rna mensageiro
MX2016014921A (es) 2014-05-15 2017-07-28 Insmed In Incorporated Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3148552B1 (en) 2014-05-30 2019-07-31 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
CN111588695A (zh) 2014-06-24 2020-08-28 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
JP6782171B2 (ja) 2014-07-02 2020-11-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド メッセンジャーｒｎａのカプセル化
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
GB201414464D0 (en) 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening
AU2015357562B2 (en) 2014-12-05 2021-10-21 Translate Bio, Inc. Messenger RNA therapy for treatment of articular disease
CA2979695A1 (en) 2015-03-19 2016-09-22 Translate Bio, Inc. Mrna therapy for pompe disease
EP3288379B1 (en) 2015-05-01 2021-11-03 Onl Therapeutics, Inc. Peptide compositions and methods of use
JP6800410B2 (ja) 2015-06-19 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー アルケニル置換２，５−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用
US11085056B2 (en) 2015-08-28 2021-08-10 Molecular Transfer, Inc. Transfection complexes and methods of using the same
EP3352800B1 (en) 2015-09-24 2022-01-05 The University of North Carolina at Chapel Hill Methods and compositions for reducing metastases
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2017147212A1 (en) 2016-02-22 2017-08-31 The Regents Of The University Of California Compositions and methods for imaging cell populations
WO2017151733A1 (en) 2016-03-01 2017-09-08 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
KR102369898B1 (ko) 2016-04-08 2022-03-03 트랜슬레이트 바이오 인코포레이티드 다량체 코딩 핵산 및 그 용도
JP2019522047A (ja) 2016-06-13 2019-08-08 トランスレイト バイオ， インコーポレイテッド オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーｒｎａ療法
IL246378A0 (en) 2016-06-21 2016-11-30 Technion Res & Dev Foundation A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer
CA3041345A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
CA3041350A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Subcutaneous delivery of messenger rna
DK3565891T3 (da) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
CA3054062A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
EP3592728A1 (en) 2017-03-07 2020-01-15 Translate Bio, Inc. Polyanionic delivery of nucleic acids
AU2018268859A1 (en) 2017-05-16 2019-12-12 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
EP3641834B1 (en) 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
EP3746496A1 (en) 2018-02-02 2020-12-09 Translate Bio, Inc. Cationic polymers
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7448488B2 (ja) 2018-05-15 2024-03-12 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの皮下送達
EP3794008A1 (en) 2018-05-16 2021-03-24 Translate Bio, Inc. Ribose cationic lipids
WO2019226925A1 (en) 2018-05-24 2019-11-28 Translate Bio, Inc. Thioester cationic lipids
JP7441802B2 (ja) 2018-05-30 2024-03-01 トランスレイト バイオ， インコーポレイテッド ビタミンカチオン性脂質
WO2019232097A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
CN112424214A (zh) 2018-05-30 2021-02-26 川斯勒佰尔公司 包含甾族部分的阳离子脂质
KR20210056953A (ko) 2018-05-30 2021-05-20 트랜슬레이트 바이오 인코포레이티드 전령 rna 백신 및 이의 용도
EP3810189A1 (en) 2018-06-19 2021-04-28 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
EP3826608A1 (en) 2018-07-23 2021-06-02 Translate Bio, Inc. Dry power formulations for messenger rna
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
EP3843709A1 (en) 2018-08-29 2021-07-07 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US20230145188A1 (en) 2018-09-14 2023-05-11 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
KR20210090634A (ko) 2018-10-19 2021-07-20 트랜슬레이트 바이오 인코포레이티드 전령 rna의 무펌프 캡슐화
WO2020097376A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
US20220016265A1 (en) 2018-11-09 2022-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
AU2019374871A1 (en) 2018-11-09 2021-05-27 Translate Bio, Inc. PEG lipidoid compounds
JP7483294B2 (ja) 2018-11-09 2024-05-15 トランスレイト バイオ， インコーポレイテッド 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
AU2019378763A1 (en) 2018-11-12 2021-06-03 Translate Bio, Inc. Methods for inducing immune tolerance
AU2019384557A1 (en) 2018-11-21 2021-06-10 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
US20230050672A1 (en) 2018-11-21 2023-02-16 Translate Bio, Inc. Cationic lipid compounds
EP3908597A1 (en) 2019-01-07 2021-11-17 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2020212522A1 (en) 2019-04-16 2020-10-22 Genfit Compositions and methods for the stabilization of micro-rna
US20220177423A1 (en) 2019-04-18 2022-06-09 Translate Bio, Inc. Cystine cationic lipids
EP3958868A4 (en) 2019-04-22 2023-01-18 The Penn State Research Foundation METHODS AND COMPOSITIONS RELATING TO THE INHIBITION OF ALDEHYDE DEHYDROGENASES FOR THE TREATMENT OF CANCER
US20220233444A1 (en) 2019-04-22 2022-07-28 Translate Bio, Inc. Thioester cationic lipids
EP3962902A1 (en) 2019-05-03 2022-03-09 Translate Bio, Inc. Di-thioester cationic lipids
EP3968952A1 (en) 2019-05-14 2022-03-23 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
WO2020243540A1 (en) 2019-05-31 2020-12-03 Translate Bio, Inc. Macrocyclic lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
US20230092238A1 (en) 2019-06-21 2023-03-23 Translate Bio, Inc. Tricine and Citric Acid Lipids
AU2020311364A1 (en) 2019-07-08 2022-02-03 Translate Bio, Inc. Improved mRNA-loaded lipid nanoparticles and processes of making the same
CA3146675A1 (en) 2019-07-23 2021-01-28 Translate Bio, Inc. Stable compositions of mrna-loaded lipid nanoparticles and processes of making
EP4003397A1 (en) 2019-07-30 2022-06-01 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
MX2022003394A (es) 2019-09-20 2022-06-22 Translate Bio Inc Arnm que codifica cftr manipulado.
EP4041400A1 (en) 2019-10-09 2022-08-17 Translate Bio, Inc. Compositions, methods and uses of messenger rna
CN115279418A (zh) 2019-10-21 2022-11-01 川斯勒佰尔公司 信使rna的组合物、方法和用途
EP4289951A3 (en) 2019-12-04 2024-03-13 Orna Therapeutics, Inc. Circular rna compositions and methods
US20230051811A1 (en) 2019-12-20 2023-02-16 Translate Bio, Inc Rectal delivery of messenger rna
JP2023508881A (ja) 2019-12-20 2023-03-06 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
CA3166420A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Il2 orthologs and methods of use
CA3173035A1 (en) 2020-02-25 2021-09-02 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
JP2023524767A (ja) 2020-05-07 2023-06-13 トランスレイト バイオ， インコーポレイテッド ＳＡＲＳ－ＣｏＶ－２抗原をコードする最適化されたヌクレオチド配列
WO2021226468A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021231697A1 (en) 2020-05-14 2021-11-18 Translate Bio, Inc. Peg lipidoid compounds
JP2023526284A (ja) 2020-05-15 2023-06-21 トランスレイト バイオ， インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子製剤
CA3179423A1 (en) 2020-05-19 2021-11-25 Robert Alexander WESSELHOEFT Circular rna compositions and methods
IT202000012055A1 (it) 2020-05-22 2021-11-22 Milano Politecnico Dispositivo, metodo e composizione per la trasfezione di cellule con acidi nucleici
WO2022006527A1 (en) 2020-07-02 2022-01-06 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
CN116322754A (zh) 2020-08-05 2023-06-23 辛德凯因股份有限公司 Il10ra结合分子及使用方法
US20230272090A1 (en) 2020-08-05 2023-08-31 Sandro Vivona Il2rb binding molecules and methods of use
EP4192502A1 (en) 2020-08-05 2023-06-14 Synthekine, Inc. Compositions and methods related to il27 receptor binding
JP2023544197A (ja) 2020-10-06 2023-10-20 トランスレイト バイオ， インコーポレイテッド 脂質ナノ粒子の改善された方法および製剤
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
EP4225272A1 (en) 2020-10-12 2023-08-16 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
AU2021373892A1 (en) 2020-11-09 2023-07-06 Translate Bio, Inc. Improved compositions for delivery of codon-optimized mrna
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
IL303165A (en) 2020-11-25 2023-07-01 Translate Bio Inc Stable liquid formulations of lipid nanoparticles
WO2022155404A1 (en) 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
EP4313115A1 (en) 2021-03-25 2024-02-07 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
CA3215606A1 (en) 2021-04-19 2022-10-27 Shrirang KARVE Improved compositions for delivery of mrna
EP4362920A1 (en) 2021-07-01 2024-05-08 Translate Bio, Inc. Compositions for delivery of mrna
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023086893A1 (en) 2021-11-10 2023-05-19 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2023214405A1 (en) 2022-05-01 2023-11-09 Yeda Research And Development Co. Ltd. Reexpression of hnf4a to alleviate cancer-associated cachexia
WO2023235392A1 (en) 2022-06-02 2023-12-07 Perkinelmer Health Sciences, Inc. Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5889953A (en) * 1995-05-25 1999-03-30 Cabletron Systems, Inc. Policy management and conflict resolution in computer networks

Also Published As

Publication number Publication date
ATE178584T1 (de) 1999-04-15
JP3210019B2 (ja) 2001-09-17
WO1994005624A1 (en) 1994-03-17
ES2132253T3 (es) 1999-08-16
EP0656883B1 (en) 1999-04-07
EP0656883A4 (en) 1995-08-09
CA2141334C (en) 2003-03-18
JPH08509953A (ja) 1996-10-22
US5334761A (en) 1994-08-02
EP0656883A1 (en) 1995-06-14
CA2141334A1 (en) 1994-03-17
DE69324367D1 (de) 1999-05-12
GR3030206T3 (en) 1999-08-31
DE69324367T2 (de) 1999-09-23

Similar Documents

Publication Publication Date Title
DK0656883T3 (da) Kationiske lipider
DK0758248T3 (da) Formuleringer til faktor IX
DE69423915D1 (de) Dichtgepackte polykationische ammonium, sulfonium und phosphonium lipide
ATE216590T1 (de) Arzneimittelformulierungen für il-12
MX9304756A (es) 9-[(glicilo substituido)amido]-6-desmetil-6-desoxitetraciclinas, metodo para su produccion y composiciones farmaceuticas que las contienen.
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
NO912630D0 (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler.
MX9304646A (es) Nuevas 7-(sustituido)-8-(sustituido)d-9-[(glicilo sustituido)amido]-6-desmetil-6-desoxitetraciclinasy metodo para su produccion.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
MX9709240A (es) Fenilpiridazinonas.
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
PT618190E (pt) 9-¬glicil substituido)amido|-6-(substituido)-5-hidroxi-6-desoxitetraciclinas
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
PL318282A1 (en) Benzoyl derivatives and method of obtaining them
CA2160961A1 (fr) Nouveaux composes amides tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
AU5933080A (en) 1-alkadienyl-2hydroxymethyl-3,4,5-trihydroxy- piperidine compounds
ES2192610T3 (es) Aminouracilos substituidos.
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
BG100248A (en) Squalene synthetase inhibitors
AP9400632A0 (en) Ether derivatives.
PT80221A (en) Improved process for preparing benzamide derivatives useful as anticonvulsant agents
ATE166642T1 (de) 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln